The identification of clinically relevant markers and therapeutic targets

Drug Discovery Today

Volumn 8, Issue 1, 2003, Pages 31-38

  Nicolette, Charles A ^a   Miller, Glenn A ^b  

^a GENZYME CORPORATION   (United States)

^b Genzyme Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; NUCLEIC ACID; TUMOR ANTIGEN; TUMOR MARKER;

CANCER THERAPY; CLINICAL PRACTICE; GENE EXPRESSION; GENE LIBRARY; PATIENT CARE; REVIEW; SEROLOGY; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037252179     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02543-6     Document Type: Review

References (42)

1. Thomas C.M.G., Sweep C.G.J. Serum tumor markers: past, state of the art, and future. Int. J. Biol. Markers. 16:2001;73.
2. Bates S.E. Clinical applications of serum tumor markers. Ann. Intern. Med. 115:1991;623-638.
3. Sox H.C. Probability theory in the use of diagnostic tests. An introduction to critical study of the literature. Ann. Intern. Med. 104:1986;60-66.
4. Bast R.C., et al. CA 125: the past and the future. Int. J. Biol. Markers. 13:1998;179-187.
5. Guadagni F., et al. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation. Int. J. Cancer. 72:1997;49-54.
6. McLaughlin R., et al. Are elevated levels of the tumour marker CA19-9 of any clinical significance? - an evaluation. Ir. J. Med. Sci. 168:1999;124-126.
7. Colomer R., et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res. Treat. 13:1989;123-133.
8. Wu J.T. Serum alpha-fetoprotein and its lectin reactivity in liver diseases: a review. Ann. Clin. Lab. Sci. 20:1990;98-105.
9. Stamey T.A., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317:1987;909-916.
10. Einhorn N., et al. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. Acta Oncol. 28:1989;655-657.
11. Soper J.T., et al. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet. Gynecol. 75:1990;249-254.
12. Velculescu V.E., et al. Serial analysis of gene expression. Science. 270:1995;484-487.
13. Li X., et al. DNA microarrays: their use and misuse. Microcirculation. 9:2002;13-22.
14. Ermolaeva O.D., Sverdlov E.D. Subtractive hybridization, a technique for extraction of DNA sequences distinguishing two closely related genomes: critical analysis. Genet. Anal. 13:1996;49-58.
15. Speicher M.R. Microsatellite instability in human cancer. Oncol. Res. 7:1995;267-275.
16. Laird P.W., Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu. Rev. Genet. 30:1996;441-464.
17. Chanock S. Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease. Dis. Markers. 17:2001;89-98.
18. Issaq H.J., et al. The SELDI-TOF MS Approach to Proteomics: Protein Profiling and Biomarker Identification. Biochem. Biophys. Res. Commun. 292:2002;587-592.
19. Poon T.C., Johnson P.J. Proteome analysis and its impact on the discovery of serological tumor markers. Clin. Chim. Acta. 313:2001;231-239.
20. de Wildt R.M., et al. Antibody arrays for high-throughput screening of antibody-antigen interactions. Nat. Biotechnol. 18:2000;989-994.
21. Miller J.C., et al. The application of protein microarrays to serum diagnostics: prostate cancer as a test case. Dis. Markers. 17:2001;225-234.
22. Yeoh E.-J., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 1:2002;133-143.
23. Zhang L., et al. Gene expression profiles in normal and cancer cells. Science. 276:1997;1268-1272.
24. Argani P., et al. Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 61:2001;4320-4324.
25. Porter D., et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 61:2001;5697-5702.
26. Buckhaults P., et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res. 61:2001;6996-7001.
27. Miksicek R., et al. Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium. Cancer Res. 62:2002;2736-2740.
28. Nacht M., et al. Molecular characteristics of non-small cell lung cancer. Proc. Natl. Acad. Sci. U. S. A. 98:2001;15203-15208.
29. St. Croix B., et al. Genes expressed in human tumor epithelium. Science. 289:2000;1197-1202.
30. Saha S., et al. A phosphatase associated with metastasis of colorectal cancer. Science. 294:2001;1343-1346.
31. Stroun M., et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 46:1989;318-322.
32. Sorenson G.D., et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomarkers Prev. 3:1994;67-71.
33. Vashioukhin V., et al. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukemia. Br. J. Hematol. 86:1994;774-779.
34. Fleischhacker M. The 2nd International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS-2). Eur. J. Med. Res. 6:2001;364-368.
35. Sahin U., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. U. S. A. 92:1995;11810-11813.
36. Taylor D.D., Gercel-Taylor C. Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? Oncol. Rep. 5:1998;1519-1524.
37. Mccoy J.L., et al. Cell-mediated immunity to tumor-associated antigensis a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res. Treat. 60:2000;227-234.
38. Springer G.F., et al. Pancarcinoma T and Tn epitopes: autoimmunogens and diagnostic markers that reveal incipient carcinomas and help establish prognosis. Immunol. Ser. 53:1990;587-612.
39. Pfreundschuh M. Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer Chemother. Pharmacol. (Suppl). 46:2000;S3-7.
40. Clemente C.G., et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 77:1996;1303-1310.
41. Ioannides C.G., Whiteside T.L. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin. Immunol. Immunopathol. 66:1993;91-106.
42. Lawendowski C.A., et al. Solid-Phase Epitope REcovery: A high throughput method for antigen identification and optimization. J. Immunol. 169:2002;2414-2421.